The striking effect of the Heart Outcomes Prevention Evaluation (HOPE) on ramipril prescribing in Ontario

CMAJ. Canadian Medical Association Journal

Volumn 168, Issue 5, 2003, Pages 553-557

  Tu, Karen ^a   Mamdani, Muhammad M ^a   Jacka, Robert M ^a   Forde, Natalie J ^a   Rothwell, Deanna M ^a   Tu, Jack V ^a,b  

^a INSTITUTE FOR CLINICAL EVALUATIVE SCIENCES   (Canada)

^b SUNNYBROOK RESEARCH INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; RAMIPRIL;

AGED; ARTICLE; CANADA; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DRUG EFFICACY; DRUG INDICATION; GERIATRIC PATIENT; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; OUTCOMES RESEARCH; PRESCRIPTION; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

EID: 0037418359     PISSN: 08203946     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987;316:1429-35.
2. Garg R, Yusuf S, for the Collaborative Group on ACE Inhibitor Trials. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. JAMA 1995;273:1450-6.
3. ACE Inhibitor Myocardial Infarction Collaborative Group. Indications for ACE inhibitors in the early treatment of acute myocardial infarction: systematic overview of individual data from 100,000 patients in randomized trials. Circulation 1998;97:2202-12.
4. Mathiesen ER, Hommel E, Giese J, Parving HH. Efficacy of captopril in postponing nephropathy in normotensive insulin dependent diabetic patients with microalbuminuria. BMJ 1991;303:81-7.
5. Giatras I, Lau J, Levey AS. Effect of angiotensin-converting enzyme inhibitors on the progression of nondiabetic renal disease: a meta-analysis of randomized trials. Angiotensin-Converting-Enzyme Inhibition and Progressive Renal Disease Study Group. Ann Intern Med 1997;127:337-45.
6. Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Lancet 2000;355:1955-64.
7. Furberg CD, Pitt B. Are all angiotensin-converting enzyme inhibitors interchangeable? J Am Coll Cardiol 2001;37:1456-60.
8. Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Evaluation and Management of Heart Failure). Guidelines for the evaluation and management of heart failure. Circulation 1995;92:2764-84.
9. Ryan TJ, Antman EM, Brooks NH, Califf RM, Hillis LD, Hiratzka LF, et al. 1999 update: ACC/AHA guidelines for the management of patients with acute myocardial infarction: executive summary and recommendations: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction). Circulation 1999;100:1016-30.
10. Meltzer S, Leiter L, Daneman D, Gerstein HC, Lau D, Ludwig S, et al. 1998 clinical practice guidelines for the management of diabetes in Canada. Canadian Diabetes Association. CMAJ 1998;159(Suppl 8):S1-29.
11. Ramsay LE, Williams B, Johnston GD, MacGregor GA, Poston L, Potter JF, et al. British Hypertension Society guidelines for hypertension management 1999: summary. BMJ 2002;319:630-5.
12. McAlister FA, Levine M, Zarnke KB, Campbell N, Lewanczuk R, Leenen F, et al. The 2000 Canadian recommendations for the management of hypertension: Part one - therapy. Can J Cardiol 2001;17:543-59.
13. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G, the Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000;342:145-53.
14. Heart Outcomes Prevention Evaluation Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 2000;355:253-9.
15. Papp L. Researchers call off $11-million heart study. Toronto Star 1999 May 8;Sect A:5.
16. Papp L. Aborted vitamin E study will be given second look. Toronto Star 1999 May 11;Sect A:5.
17. Talaga T. Pill cuts heart deaths 22%, study says. Toronto Star 1999 Sept 1; Sect A:5.
18. Lamas GA, Pfeffer MA, Hamm P, Wertheimer J, Rouleau JL, Braunwald E. Do the results of randomized clinical trials of cardiovascular drugs influence medical practice? The SAVE Investigators. N Engl J Med 1992;327:241-7.
19. Mamdani MM, Tu JV. Did the major clinical trials of statins affect prescribing behaviour? CMAJ 2001;164:1695-6.
20. Jackevicius CA, Anderson GM, Leiter L, Tu JV. Use of statins in patients after acute myocardial infarction. Arch Intern Med 2001;161:183-8.
21. Hux JE, Ivis F, Flintoft V, Bica A. Diabetes in Ontario: determination of prevalence and incidence using a validated administrative data algorithm. Diabetes Care 2002;25:512-6.
22. Pindyck RS, Rubinfeld DL. Econometric models and economic forecasts. New York: Irwin McGraw-Hill; 1998: p. 463-601.
23. Dickey DA, Fuller WA. Distribution of the estimators for autoregressive time series with a unit root. JASA 1979;74:427-31.
24. Ljung GM, Box GEP. On a measure of lack of fit in time-series models. Biometrika 1978;65:297-303.
25. Wang TJ, Ausiello JC, Stafford RS. Trends in antihypertensive drug advertising, 1985-1996. Circulation 1999;99:2055-7.